Skip to content

SYRA HEALTH CORP.: 10-Q filed 2025-11-12

What SYRA HEALTH CORP. reported in its quarterly report filed 2025-11-12 (fiscal Q3 2025): 37 published measures, 114 facts as tagged in accession 0001493152-25-022023.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-12
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-022023 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SYRA HEALTH CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-303,263,217USD
At 2024-12-313,679,332USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,053,829USD
At 2024-12-31800,761USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-302,209,388USD
At 2025-06-302,414,163USD
At 2025-03-312,456,636USD
At 2024-12-312,878,571USD
At 2024-09-303,330,653USD
At 2024-06-302,092,270USD
At 2024-03-313,449,305USD
At 2023-12-314,013,211USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-301,976,545USD
At 2024-12-312,395,405USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-225,902USD92
2025-01-01 to 2025-09-30-761,763USD273
2025-04-01 to 2025-06-30-63,596USD91
2025-01-01 to 2025-03-31-472,265USD90
2024-07-01 to 2024-09-30-417,535USD92
2024-01-01 to 2024-09-30-3,254,841USD274
2024-04-01 to 2024-06-30-1,390,256USD91
2024-01-01 to 2024-03-31-1,447,050USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-158,554USD273
2024-01-01 to 2024-09-30-2,717,313USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-09-3011,111USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,687,971USD92
2025-01-01 to 2025-09-305,491,944USD273
2024-07-01 to 2024-09-302,253,336USD92
2024-01-01 to 2024-09-305,975,357USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,687,971USD92
2025-01-01 to 2025-09-305,491,944USD273
2024-07-01 to 2024-09-302,253,336USD92
2024-01-01 to 2024-09-305,975,357USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-260,306USD273
2024-01-01 to 2024-09-302,145,808USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-11,111USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-9,585,956USD
At 2024-12-31-8,824,193USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3011,939,169shares92
2025-01-01 to 2025-09-3011,823,089shares273
2024-07-01 to 2024-09-307,264,768shares92
2024-01-01 to 2024-09-306,789,209shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3011,939,169shares92
2025-01-01 to 2025-09-3011,823,089shares273
2024-07-01 to 2024-09-307,264,768shares92
2024-01-01 to 2024-09-306,789,209shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.02USD/shares92
2025-01-01 to 2025-09-30-0.06USD/shares273
2024-07-01 to 2024-09-30-0.06USD/shares92
2024-01-01 to 2024-09-30-0.48USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.02USD/shares92
2025-01-01 to 2025-09-30-0.06USD/shares273
2024-07-01 to 2024-09-30-0.06USD/shares92
2024-01-01 to 2024-09-30-0.48USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-309,176USD
At 2024-12-3127,347USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-3075,194USD273
2024-01-01 to 2024-09-3028,486USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-232,171USD92
2025-01-01 to 2025-09-30-768,663USD273
2024-07-01 to 2024-09-30-428,910USD92
2024-01-01 to 2024-09-30-3,263,217USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-303,210,591USD
At 2024-12-313,352,795USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-301,053,829USD
At 2024-12-31613,549USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30926,255USD
At 2024-12-31680,827USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30786,712USD92
2025-01-01 to 2025-09-302,665,255USD273
2024-07-01 to 2024-09-301,097,208USD92
2024-01-01 to 2024-09-304,581,301USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30554,541USD92
2025-01-01 to 2025-09-301,896,592USD273
2024-07-01 to 2024-09-30668,298USD92
2024-01-01 to 2024-09-301,318,084USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-30252,384USD92
2025-01-01 to 2025-09-30828,741USD273
2024-07-01 to 2024-09-30288,305USD92
2024-01-01 to 2024-09-301,267,634USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30816USD92
2025-01-01 to 2025-09-3067,701USD273
2024-07-01 to 2024-09-3034,821USD92
2024-01-01 to 2024-09-30590,263USD274

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-301,976,545USD
At 2024-12-312,395,405USD
At 2024-09-302,697,459USD
At 2023-12-313,280,075USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3011,783,405USD
At 2024-12-3111,692,952USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-3043,450USD
At 2024-12-31299,190USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-3043,450USD
At 2024-12-31299,190USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-30144,735USD
At 2024-12-31126,564USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-30224,692USD
At 2024-12-31230,383USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30307,791USD
At 2024-12-31276,563USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,396USD92
2025-01-01 to 2025-09-3018,171USD273
2024-07-01 to 2024-09-3025,541USD92
2024-01-01 to 2024-09-3055,460USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,905USD92
2025-01-01 to 2025-09-308,992USD273
2024-07-01 to 2024-09-302,266USD92
2024-01-01 to 2024-09-3010,072USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-306,269USD92
2025-01-01 to 2025-09-306,900USD273
2024-07-01 to 2024-09-3011,375USD92
2024-01-01 to 2024-09-308,376USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-308,992USD273
2024-01-01 to 2024-09-3010,072USD274

Inspect the source

Entity
SYRA HEALTH CORP. / CIK 0001922335
Captured
2026-09-21T17:41:11.939Z
SEC response SHA-256
b7deb50e336dc97b3dc95be11b8ad17619851faa670b1bd5b706682829760083

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001922335.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))